The Conference on Cell & Gene Therapy for HIV Cure is supported by the following organizations:




amfAR, The Foundation for AIDS Research, is one of the world’s leading nonprofit organizations dedicated to the support of AIDS research, HIV prevention, treatment education, and the advocacy of sound AIDS related public policy. Since 1985, amfAR has invested more than $450 million in its programs and has awarded more than 3,300 grants to research teams worldwide.

Among many accomplishments, amfAR supported early studies that led to the development of four of the six main classes of anti-HIV drugs that allow people living with HIV/AIDS to live longer, healthier lives, and amfAR pioneered the research that led to the use of antiretroviral drugs to prevent mother-to-child transmission of HIV.

Today amfAR’s research focus is on the search for a cure for HIV/AIDS.  Following the establishment of the amfAR Research Consortium on HIV Eradication (ARCHE) in 2010, amfAR launched the Countdown to a Cure for AIDS initiative.  Backed by a $100 million research investment strategy, the Countdown is aimed at developing the scientific basis for a cure by 2020.


Abbott Molecular is an emerging leader in molecular diagnostics and the analysis of DNA, RNA, and proteins at the molecular level. We are committed to exploring new clinical frontiers through the development and delivery of system and assay solutions that are designed to provide earlier disease diagnosis, selection of appropriate therapies and monitoring of disease recurrence. Our expanding portfolio brings multiples technologies that enable fast, accurate results. Our state of the art research and manufacturing facilities have hundreds of scientists who are dedicated to producing quality and reliable products.

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.

Our portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.

Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered zinc finger DNA-binding proteins (ZFPs) as novel ZFP Therapeutics® targeting various monogenic and infectious diseases with unmet medical needs.

We are worldwide leaders in the development of our proprietary ZFP technology platform that enables highly specific regulation of gene expression and genome modification. Our technology platform is based on a naturally occurring class of transcription factors, ZFPs, which we can engineer to bind to any DNA sequence with singular specificity and drive desired therapeutic outcomes.

Our ZFPs can be linked to functional domains that normally activate or repress gene expression to create ZFP transcription factors (ZFP TFs) capable of turning genes on or off. We can also link ZFPs to endonuclease domains to create zinc finger nucleases (ZFNs) which enable precise genome editing in cells. Sangamo's engineered ZFNs can modify a cell's DNA at a precise location, thereby facilitating the correction or disruption of a specific gene or the targeted addition of a new DNA sequence, without the unwanted consequences of off-target DNA binding activity.